1. Reconciling Antimicrobial Susceptibility Testing and Clinical Response in Antimicrobial Treatment of Chronic Cystic Fibrosis Lung Infections.
- Author
-
Waters VJ, Kidd TJ, Canton R, Ekkelenkamp MB, Johansen HK, LiPuma JJ, Bell SC, Elborn JS, Flume PA, VanDevanter DR, and Gilligan P
- Subjects
- Chronic Disease drug therapy, Cystic Fibrosis microbiology, Humans, Lung drug effects, Lung microbiology, Microbial Sensitivity Tests, Pseudomonas aeruginosa drug effects, Respiratory Tract Infections drug therapy, Respiratory Tract Infections microbiology, Sputum microbiology, Anti-Bacterial Agents pharmacology, Anti-Bacterial Agents therapeutic use, Cystic Fibrosis drug therapy, Pseudomonas Infections drug therapy
- Abstract
Median cystic fibrosis (CF) survival has increased dramatically over time due to several factors, including greater availability and use of antimicrobial therapies. During the progression of CF lung disease, however, the emergence of multidrug antimicrobial resistance can limit treatment effectiveness, threatening patient longevity. Current planktonic-based antimicrobial susceptibility testing lacks the ability to predict clinical response to antimicrobial treatment of chronic CF lung infections. There are numerous reasons for these limitations including bacterial phenotypic and genotypic diversity, polymicrobial interactions, and impaired antibiotic efficacy within the CF lung environment. The parallels to other chronic diseases such as non-CF bronchiectasis are discussed as well as research priorities for moving forward., (© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.)
- Published
- 2019
- Full Text
- View/download PDF